Table 1.
General characteristics of the study population broken down per disease: Rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
| RA n=250 |
AS n=119 |
PsA n=109 |
pa | |
|---|---|---|---|---|
| Age (year), mean±SD | 53.8±13.9 | 42.6±12.2 | 47.6±12.1 | 0.000 |
| Sex, n (%) | ||||
| Female | 173 (69.2) | 25 (21.0) | 58 (5.2) | 0.000 |
| Male | 77 (30.8) | 94 (79.0) | 51 (46.8) | |
| Length of disease evolution in years, mean±SD | 8.6±7.8 | 7.6±8.2 | 8.0±8.1 | 0.057 |
| Comorbidities (Charlson Index)b | ||||
| Between 0 and 3 | 70 (28.0) | 56 (47.4) | 45 (41.3) | 0.000 |
| Between 4 and 9 | 121 (48.4) | 51 (42.8) | 52 (47.7) | |
| ≥10 | 59 (23.6) | 12 (10.0) | 12 (11.0) | |
| Smokerc, n (%) | ||||
| Yes | 40 (16.0) | 32 (26.8) | 23 (21.1) | 0.017 |
| No | 135 (54.0) | 54 (45.3) | 38 (34.8) | |
| No data available | 75 (30.00) | 33 (27.7) | 48 (44.0) | |
| DAS28/BASDAI, mean±SD | n=134 | n=67 | n=36 | –d |
| 5.2±1.1 | 6.0±1.6 | 5.2±1.5 | ||
| ESR (mm/h), median (IR) | n=235 | n=112 | n=100 | 0.000 |
| 28 (2–140) | 13 (1–140) | 19 (1–101) | ||
| CRP (mg/l), median (IR) | n=232 | n=116 | n=96 | 0.039 |
| 9 (0–114) | 7 (0–120) | 5 (0–143) | ||
| Hemoglobin (mg/dl), mean±SD | n=243 | n=115 | n=103 | 0.000 |
| 13.1±1.5 | 14.2±1.5 | 13.2±1.6 | ||
| Concomitant MTX, n (%) | n=247 | n=76 | n=109 | 0.000 |
| 126 (51.0) | 6 (7.9) | 54 (49.5) | ||
| Concomitant leflunomide, n (%) | n=237 | n=116 | n=108 | 0.000 |
| 32 (13.5) | 1 (0.9) | 8 (7.4) | ||
| Concomitant GC, n (%) | n=242 | n=117 | n=104 | 0.000 |
| 204 (84.3) | 19 (16.2) | 62 (59.6) | ||
| Daily GC dose (mg), mean±SDe | n=242 | n=117 | n=104 | 0.000 |
| 7.4±5.7 | 1.4±3.6 | 4.6±5.1 | ||
| Biological therapy, n (%) | ||||
| Adalimumab | 82 (32.8) | 58 (48.7) | 56 (51.4) | –f |
| Etanercept | 65 (26.0) | 43 (36.1) | 29 (26.6) | |
| Abatacept | 34 (13.6) | 0 (0.0) | 0 (0.0) | |
| Tocilizumab | 28 (11.2) | 0 (0.0) | 3 (2.8) | |
| Infliximab | 7 (2.8) | 1 (0.8) | 4 (3.7) | |
| Golimumab | 15 (6.0) | 13 (10.9) | 11 (10.1) | |
| Certolizumab | 19 (7.6) | 4 (3.4) | 3 (2.8) | |
| Ustekinumab | 0 (0.0) | 0 (0.0) | 3 (2.8) | |
The total number of BT lines was 478. The values in this table represent the number of lines for which data were available. AS: ankylosing spondylitis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CRP: C-reactive protein; DAS28: Disease Activity Index 28; ESR: erythrocyte sedimentation rate; GC: glucocorticoid; IR: interquartile range; n: number of BT lines; PsA: psoriatic arthritis; RA: rheumatoid arthritis; SD: standard deviation.
Values were considered statistically significant when p<0.05.
Validated index to measure prognostic comorbidity in clinical studies
Active smoker at the beginning of biological treatment
No statistical test could be used because of the differences between the scores applied in each disease.
All glucocorticoid doses were converted to an equivalent prednisone dose.
Test could not be conducted because some of the observed values in each cell were<5.